Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
R1507 plus erlotinib versus placebo plus erlotinib in advanced non-small cell lung cancer
2008-001736-12Phase 2Completed
- Sponsor
- Roche
- Start
- Jul 2008
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of teprotumumab in non-small cell lung cancer (NSCLC) (3 arms), sponsored by Roche. Primary endpoint: Progression-free survival at 12 weeks. Started Jul 2008; status: completed.
02
Drugs
teprotumumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2008-001736-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-001736-12.